Author

R. Brody

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Bioengineering· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2 Research Focus:cell-cell communication· 2 Assay:proteomics· 2

Frequent Co-Authors

K. G. Beaumont· 3 shared M. Garcia-Barros· 3 shared S. Kim-Schulze· 3 shared a. horowitz· 2 shared A. M. Farkas· 2 shared A. Tocheva· 2 shared B. Lee· 2 shared B. Salome· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

K. G. Beaumont

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Single cell view of tumor microenvironment gradients in pleural mesothelioma

B. Giotti, K. Dolasia, w. Zhao, P. Cai, R. Sweeney, E. Merritt, E. Kiner, G. Kim, A. Bhagwat, S. Hegde, B. Fitzgerald, S. Shroff, T. Dawson, M. Garcia-Barros, J. Abdul-Ghafar, , A. Tsankov

This paper uses single-cell RNA-sequencing to analyze the tumor microenvironment in pleural mesothelioma, identifying gene programs, fetal-like endothelial cells, and a new therapeutic target.

bioRxiv · Mar 14, 2024Cancer Biology

A multipotent cell type from term human placenta

S. Vadakke-Madathil, E. Bouhamida, B. Wang, P. Mathiyalagan, P. Ayyamperumal, A. Khan, M. Oniskey, C. Santos-Gallego, M. Hadley, L. Croft, F. Dekio, J. Tripodi, V. Najfeld, R. Brody, S. Gelber, , H. W. Chaudhry

The paper identifies multipotent CDX2 cells from term human placentas that can differentiate into cardiovascular lineages and restore cardiac function in a mouse model.

bioRxiv · Aug 2, 2023 · PreprintCell Biology

Elevated HLA-E and NKG2A as a consequence of chronic immune activation defines resistance to M. bovis BCG immunotherapy in Non-Muscle-Invasive Bladder Cancer

D. Ranti, Y.-S. Wang, J. Daza, C. Bieber, B. Salome, E. Merritt, J.-A. Cavallo, E. Hegewisch-Solloa, E. M. Mace, A. M. Farkas, S. Schroff, B. Lee, M. Tran, T. Strandgaard, S. V. Lindskrog, , A. Horowitz

The paper identifies elevated HLA-E and NKG2A as markers of resistance to BCG immunotherapy in NMIBC, linked to immune escape mechanisms.

bioRxiv · Mar 6, 2022 · PreprintImmunology

NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer

B. Salome, J. P. Sfakianos, J. Daza, A. Charap, C. Hammer, R. Banchereau, A. M. Farkas, D. Geanon, G. Kelly, R. M. de Real, B. Lee, K. G. Beaumont, S. Shroff, Y. S. A. Wang, Y.-C. Wang, , Mariath

This study identifies NKG2A and HLA-E as an alternative immune checkpoint axis in bladder cancer, showing NKG2A+ CD8 T cells can bypass HLA-ABC loss through TCR-independent cytotoxicity.

bioRxiv · Mar 4, 2022 · PreprintImmunology

Maternal cytokine response after SARS-CoV-2 infection during pregnancy

F. A. J. Gigase, N. M. Molenaar, R. D. Missall, A.-S. Rommel, W. Lieb, E. Ibroci, S. Ohrn, J. Lynch, F. Krammer, R. Brody, R. H. Jessel, R. S. Sperling, C. Lesseur, F. Callipari, R. R. Galang, , L. D. De Witte

This study examines if SARS-CoV-2 infection during pregnancy leads to lasting changes in maternal cytokine levels, finding no significant differences between infected and uninfected groups.

bioRxiv · Jan 4, 2022 · PreprintImmunology

Development of a Surface Programmable Activation Receptor system (SPAR): A living cell biosensor for rapid pathogen detection

J. D. Kittle, J. S. Lwande, M. R. Williams, R. Brody, M. Frenchmeyer, J. Hua, S. Liang, K. McQuaide, M. Mo, A. Neese, Y. Tang, S. Vedamoorthy, L. Zeng, T. Zupancic, C. McBrairty

The paper develops a biosensor platform called SPAR for rapid and sensitive pathogen detection using engineered cells and antibodies.

bioRxiv · Jun 30, 2019 · PreprintBioengineering